People who have had coronavirus release a sufficient amount of antibodies after the first dose of the vaccine is administered. This fact made scientists think about the uselessness of a second COVID-19 vaccination for those who have survived the infection, writes The Wall Street Journal.
So, the study was conducted at the University of Maryland School of Medicine. The experiment involved 59 health workers. Of these, 42 who had recovered from the coronavirus developed more powerful immunity after the first vaccine than 17 people who have not yet had the infection. It is noted that, on average, those who have recovered after the first injection release the same amount of antibodies as those who received both vaccinations, but did not suffer COVID-19.
A study conducted at the Icahn School of Medicine at Mount Sinai Medical Center and Fred Hutchinson Cancer Research Center in Seattle confirms these results.
As the newspaper writes, the transition to one dose for those who have recovered will allow the drugs to be redistributed in such a way that they will be enough for more people. Moreover, such a restructuring will require a lot of time and money, as it is necessary to conduct additional research in this area.
Earlier, the General Director of the Vector Center, Rinat Maksyutov, said that the Russian vaccine EpiVacCorona after vaccination gives immunity to coronavirus for a year.